GET DAILY SIGNALSFocalTherics (FOCL) Holds Near $4.32 After +2.9% Gain Over 30 Days
Key Takeaways
- FocalTherics (FOCL), formerly EDAP TMS, traded near $4.32, posting a modest gain of roughly 2.9% over the trailing 30 days after its rebrand as a pure-play robotic focal therapy company.
- The stock has moved within a narrow range of about $4.00 to $4.75, indicating balanced investor views ahead of the next earnings report.
- Second-quarter 2026 HIFU revenue increased 39% year-over-year to $13.2 million, with gross margin rising to 55.6%.
- Management kept full-year 2026 HIFU revenue guidance at $50 million to $54 million, pointing to 34% to 45% growth.
- Third-quarter 2026 results are set for release after market close on November 5, 2026, positioning earnings as the main near-term catalyst.
- Operating losses and funding needs stay the key risks, even with the company aiming for a 40% revenue CAGR through 2028.
- For additional detail on valuation, results, and projections, explore FocalTherics Price Targets, Earnings, and Forecast pages.
- To review how automated strategies are positioned across the market, explore Trending AI Robots.
Current Market Snapshot
FOCL shares have shown limited volatility over the past month, holding near $4.32 after closing around $4.20 roughly 30 days earlier. The +2.9% advance points to a phase of consolidation rather than any strong directional shift, with the stock continuing to trade in a band between about $4.00 and $4.75 on relatively modest daily volume. As a small-cap medical technology name, FOCL remains sensitive to clinical data releases, quarterly results, and broader healthcare-sector sentiment, all of which have kept attention focused ahead of the upcoming earnings report.
FocalTherics Business Overview and Competitive Position
FocalTherics, whose legal name remains EDAP TMS S.A., develops, manufactures, and markets minimally invasive medical devices that rely on proprietary focused ultrasound technology. Its flagship platform, Focal One® Robotic HIFU, integrates advanced imaging, real-time treatment planning, and robotic precision to deliver personalized focal therapy for localized prostate cancer while seeking to preserve urinary and sexual function. In mid-2026 the company adopted the FocalTherics identity and shifted its Nasdaq listing from EDAP to FOCL, treating legacy lithotripsy (ESWL) and distribution segments as discontinued operations to concentrate solely on high-growth robotic focal therapy. The platform has seen adoption at major academic and community institutions, backed by expanding clinical evidence, growing reimbursement, and early work on additional indications.
Recent Developments Shaping FOCL
A number of confirmed developments have influenced investor sentiment in recent months. The corporate rebrand and ticker change to FOCL, effective June 1, 2026, sharpened focus on the Focal One platform. In August the company reported second-quarter results with HIFU revenue of $13.2 million, a 39% year-over-year rise, a gross margin of 55.6%, and reaffirmed 2026 guidance of $50 million to $54 million. It also completed a $40 million equity financing round to support commercial expansion, research, and new indications. On October 22, 2026, FocalTherics announced third-quarter results would be released on November 5, 2026, directing attention to the near-term print. Earlier catalysts, including FDA 510(k) clearance for the latest Focal One evolution and a collaboration with Telix on PSMA-PET imaging in robotic HIFU and theranostics, highlight ongoing clinical and commercial progress. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
2026 Outlook and Key Investor Focus Areas
The main near-term event remains the third-quarter 2026 earnings release scheduled for November 5, 2026, which will offer insight into HIFU system placements, procedure volumes, gross margin trends, and whether full-year guidance of $50 million to $54 million stays on track. Investors will also track progress toward the stated 40% revenue CAGR target through 2028, expansion of the U.S. installed base, and development of newer indications such as BPH and endometriosis. Key risks continue to include ongoing operating losses, balance-sheet and funding considerations, the pace of reimbursement adoption, and competitive dynamics in the broader prostate cancer treatment market. Analyst attention stays centered on whether commercial execution can convert rising procedure demand into improved profitability over time.
Exploring AI Trading Tools
In my regular research process, I often review Tickeron’s AI Trading Bots to understand how automated strategies are positioned across the market. The platform provides a selection of bots with varying approaches, timeframes, and performance metrics that can complement traditional analysis. It has become a useful reference point when evaluating data-driven perspectives on individual names and broader sectors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
FOCL's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for FOCL turned positive on October 21, 2026. Looking at past instances where FOCL's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 56 cases where FOCL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on FOCL as a result. In 73 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
FOCL moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where FOCL advanced for three days, in 185 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 50-day moving average for FOCL moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FOCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FOCL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. FOCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: FOCL's P/B Ratio (-63.541) is slightly lower than the industry average of (12.613). P/E Ratio (-4.173) is within average values for comparable stocks, (10.633). FOCL's Projected Growth (PEG Ratio) (8.100) is very high in comparison to the industry average of (2.016). Dividend Yield (0.000) settles around the average of (0.138) among similar stocks. P/S Ratio (1.919) is also within normal values, averaging (4.260).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FOCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of minimally invasive medical devices for urological diseases
Industry MedicalDistributors
Advertisement